Advertisement

American Journal of Clinical Dermatology

, Volume 4, Issue 9, pp 623–639 | Cite as

Drug Interactions of Clinical Significance for the Dermatologist

Recognition and Avoidance
  • Lori E. Shapiro
  • Sandra R. Knowles
  • Neil H. Shear
Review Article

Abstract

While it would be impossible for any dermatologist to remember all potential drug interactions, knowledge of the mechanisms of drug interactions can help reduce the risk of serious adverse outcomes. Most drugs are associated with interactions but the majority do not produce significant outcomes. Dealing with drug interactions is a challenge in all clinical practice, including dermatology. New information continues to appear, and dermatologists need to know about the drugs they use.

This article focuses on the mechanisms of drug interactions. In particular, the life of a drug in terms of absorption, distribution, metabolism and excretion are reviewed with the focus on points of importance and relevance to drug interactions. The most clinically important drug interactions in dermatological practice are caused by alterations in drug metabolism. The contributions of P-glycoprotein, pharmacogenetic variation and genetic polymorphisms to drug interactions are highlighted, and the best evidence for drug interactions involving drug classes relevant to the dermatologist is presented.

Since the initial evidence for clinically relevant drug interactions comes from case reports, prescribing physicians can have a major role in collating information on interactions. By understanding the mechanisms behind drug interactions and staying alert for toxicities, we can help make drug therapy safer and reduce the fear of drug interactions.

Keywords

Drug Interaction Fluconazole Itraconazole Clarithromycin Ketoconazole 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

References

  1. 1.
    Shapiro LE, Shear NH. Drug interactions: how scared should we be? CMAJ 1999; 161: 1266–7PubMedGoogle Scholar
  2. 2.
    Weideman RA, McKinney WP, Bernstein IH. Predictors of potential drug interactions. Hosp Pharm 1998; 33: 835–40Google Scholar
  3. 3.
    Jankel CA, Gitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 1993; 9: 51–9PubMedCrossRefGoogle Scholar
  4. 4.
    Schneitman-McIntire O, Farnen TA, Gordon N, et al. Medication misadventures resulting in emergency department visits at an HMO medical center. Am J Health Syst Pharm 1996; 53: 1416–22PubMedGoogle Scholar
  5. 5.
    Hamilton RA, Briceland LL, Andritz MH. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacoepidemiology 1998; 18: 1112–20Google Scholar
  6. 6.
    Roos TC, Merk HF. Important drug interactions in dermatology. Drugs 2000 Feb; 59 (2): 181–92Google Scholar
  7. 7.
    Hoey J. Drug interactions: who warns the patients [editorial]? CMAJ 1999; 161: 117Google Scholar
  8. 8.
    Shapiro LE, Shear NH. Drug interactions P450. Curr Probl Dermatol 2001; 13: 141–52CrossRefGoogle Scholar
  9. 9.
    du Souich P. In human therapy, is the drug-drug interaction or the adverse drug reaction the issue? Can J Clin Pharmacol 2001; 8: 153–61PubMedGoogle Scholar
  10. 10.
    Andersen W, Feingold D. Adverse drug interactions clinically important for the dermatologist. Arch Dermatol 1995; 131: 468–73PubMedCrossRefGoogle Scholar
  11. 11.
    Del Rosso JQ. Clinically significant drug interactions: recognition and understanding of common mechanisms. Curr Pract Med 1998; 1: 62–4Google Scholar
  12. 12.
    Bonnabry P, Sievering J, Leemann T, et al. Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies. Clin Pharmacokinet 2001; 40 (9): 631–40PubMedCrossRefGoogle Scholar
  13. 13.
    Thurmann PA, Hompesch BC. Influence of gender on the pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther 1998; 36 (11): 586–90PubMedGoogle Scholar
  14. 14.
    Hoey J. Postmarketing drug surveillance: what it would take to make it work. CMAJ 2001; 165: 1293Google Scholar
  15. 15.
    Shapiro LE, Singer MI, Shear NH. Pharmacokinetic mechanisms of drug-drug and drug-food interactions in dermatology. Curr Opin Dermatol 1997; 4: 25–31Google Scholar
  16. 16.
    Singer MI, Shapiro LE, Shear NH. Cytochrome P450 3A: Interactions with dermatologic therapies. J Am Acad Dermatol 1997; 37: 765–71PubMedCrossRefGoogle Scholar
  17. 17.
    Anastasio G, Cornell K, Menscer D. Drug interactions: keeping it straight. Am Fam Physician 1997; 56: 883–94PubMedGoogle Scholar
  18. 18.
    Marchbanks C. Drug-drug interactions with fluoroquinolones. Pharmacotherapy 1993; 13: 23–5Google Scholar
  19. 19.
    Morii M, Ueno K, Ogawa A, et al. Impairment of mycophenolate mofetil absorption by iron ion. Clin Pharmacol Ther 2000; 68: 613–6PubMedCrossRefGoogle Scholar
  20. 20.
    Bodey GP. Azole antifungal drugs. Clin Infect Dis 1992; 14: 5161–9CrossRefGoogle Scholar
  21. 21.
    Zimmermann T, Yeates RA, Laufen H, et al. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994; 46: 147–50PubMedCrossRefGoogle Scholar
  22. 22.
    Blum RA, D’Andrea DT, Florentino BM. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991; 114: 755–7PubMedGoogle Scholar
  23. 23.
    Hansten PD. Drug interactions. Drug Interactions Newsletter 1996, 906Google Scholar
  24. 24.
    Abramowicz M, editor. Drug interactions. Med Lett 1999; 41: 61–2Google Scholar
  25. 25.
    Preiss R. P-glycoprotein and related transporters. Int J Clin Pharmacol Ther 1998; 36: 3–8PubMedGoogle Scholar
  26. 26.
    Benet LZ, Izumi T, Zhang Y, et al. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral delivery. J Control Release 1999; 62: 25–31PubMedCrossRefGoogle Scholar
  27. 27.
    Lown KS, Mao RR, Leicihtman AB, et al. Role of intestinal p-glycoprotein (mdr1) in interpatient variation in the oral bioavailabity of cyclosporine. Clin Pharmacol Ther 1997; 62: 248–60PubMedCrossRefGoogle Scholar
  28. 28.
    Burkhart CN. Ivermectin: an assessment of its pharmacology, microbiology and safety. J Bet Toxicol 2000; 13: 292–6Google Scholar
  29. 29.
    Watkins. Drug metabolism by cytochromes 450 in the liver and small bowel. Gastroenterol Clin North Am 1996; 21: 511–26Google Scholar
  30. 30.
    Birkett DJ, Mackenzie PI, Veronese ME, et al. In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci 1993; 14: 292–4CrossRefGoogle Scholar
  31. 31.
    Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes. Drug Metab Rev 1997; 29: 413–580PubMedCrossRefGoogle Scholar
  32. 32.
    Ford N, Sonnichsen D. Clinically significant cytochrome P-450 drug interactions: a comment. Pharmacotherapy 1998; 18: 890–1PubMedGoogle Scholar
  33. 33.
    Kolyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 1999; 37 (1): 8–19Google Scholar
  34. 34.
    Michalets E. Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy 1998; 18: 84–112PubMedGoogle Scholar
  35. 35.
    Park BK, Pirmohamed M, Kitteringham N. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Phamacol Ther 1995; 68: 385–424CrossRefGoogle Scholar
  36. 36.
    Abramowicz M, editor. Fexofenadine. Med Lett 1996; 38: 95–6Google Scholar
  37. 37.
    Monahan BP, Ferguson CL, Kelleavy ES, et al. Torsades do pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788–90PubMedCrossRefGoogle Scholar
  38. 38.
    Honig PK, Worthan DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513–8PubMedCrossRefGoogle Scholar
  39. 39.
    Cantilena LR, Sorrels S, Wiley T, et al. Fluconazole alters terfenadine pharmacokietics and electrocardiographic pharmacodynamics [abstract]. Clin Pharmacol Ther 1995; 57: 185Google Scholar
  40. 40.
    Harris S, Hilligoss DM, Colangelo PM, et al. Azithromycin and terfenadine: lack of drug interaction. Clin Pharmacol Ther 1995; 58 (3): 310–5PubMedCrossRefGoogle Scholar
  41. 41.
    Abramowicz M, editor. Grapefruit juice interactions with drugs. Med Lett 1995; 37: 73–4Google Scholar
  42. 42.
    Benton R, Honig P, Zamani K, et al. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996; 59: 383–8PubMedCrossRefGoogle Scholar
  43. 43.
    Abdel-Rahman SM, Gotschall RR, Kaufmann RE, et al. Investigation of terbinafine as a CP2D6 inhibitor in vivo. Clin Pharmacol Ther 1999; 65: 465–72PubMedCrossRefGoogle Scholar
  44. 44.
    Barner EL, Gray SL. Donepezil use in Alzheimer disease. Ann Pharmacother 1999; 32: 70–7Google Scholar
  45. 45.
    Tseng CY, Wang SL, Lai MD, et al. Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1996; 60: 177–82PubMedCrossRefGoogle Scholar
  46. 46.
    Kang BC, Yang CQ, Cho HK, et al. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm Drug Dispos 2002; 23 (2): 77–81PubMedCrossRefGoogle Scholar
  47. 47.
    Kobayashi K, Urashima K, Shimada N, et al. Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA expressed systems of the rat. Drug Metab Dispos 2003; 31 (7): 833–6PubMedCrossRefGoogle Scholar
  48. 48.
    Touchette MA, Chandrasekar PH, Milad MA, et al. Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. Br J Clin Pharmacol 1992; 34: 75–8PubMedCrossRefGoogle Scholar
  49. 49.
    Cadle RM, Zenon III GJ, Rodruguez-Bvarradas MC, et al. Fluconazole induced symptomatic phenytoin toxicity. Ann Pharmacother 1994; 28: 292–5Google Scholar
  50. 50.
    Katz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol 1999; Suppl. 56: 26–32Google Scholar
  51. 51.
    Ahonen J, Olkkola KT, Takala A, et al. Interaction between fluconazole and midazolam in intensive care patients. Acta Anaesthesiol Scand 1999; 43 (5): 509–14PubMedCrossRefGoogle Scholar
  52. 52.
    Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 64: 332–41CrossRefGoogle Scholar
  53. 53.
    Tailor S, Gupta A, Walder S, et al. Peripheral edema due to nifedipine-itraconazole interaction: a case report. Arch Dermatol 1996; 132: 350–2PubMedCrossRefGoogle Scholar
  54. 54.
    Kaukonen KM, Olkkola KT, Neuvonen PJ. Fluconazole but not itraconazole decreased the metabolism of losartan to E-3174. Eur J Clin Pharmacol 1998; 53: 445–9PubMedCrossRefGoogle Scholar
  55. 55.
    Gupta AK, Katz HI, Shear NH. Drug interactions with itraconazole, fluconazole and terbinafine and their management. J Am Acad Dermatol 1999; 41: 237–48PubMedCrossRefGoogle Scholar
  56. 56.
    Trujillo TC, Nolan PE. Antiarrhythmic agents: drug interactions of clinical significance. Drug Saf 2000; 23 (6): 509–32PubMedCrossRefGoogle Scholar
  57. 57.
    First MR, Schroeder TJ, Michael A, et al. Cyclosporine-ketoconazole interactions: long-term follow-up and preliminary results of a randomized trial. Transplantation 1993; 55: 1000–4PubMedCrossRefGoogle Scholar
  58. 58.
    Gomez D, Wacher VJ, Tomlanovich SJ, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995; 58: 15–9PubMedCrossRefGoogle Scholar
  59. 59.
    Shennib H, Auger JL. Diltiazem improves cyclosporine dosage in cystic fibrosis lung transplant recipients. J Heart Lung Transplant 1994; 10: 292–6Google Scholar
  60. 60.
    Tatro DS, editor. Drug interaction facts (with quarterly updates). St Louis: Facts and Comparisons; 1999 Jan: xxi-xxvii, 39–40, 2406–42, 720a-bGoogle Scholar
  61. 61.
    Fuhr U. Drug interactions with grapefruit juice. Drug Saf 1998; 18: 251–72PubMedCrossRefGoogle Scholar
  62. 62.
    Roller L. Drugs and grapefruit juice [letter]. Clin Pharmacol Ther 1998; 1: 87CrossRefGoogle Scholar
  63. 63.
    Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998; 63: 397–402PubMedCrossRefGoogle Scholar
  64. 64.
    Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral bioavailability of CYP3A4 substrates by grapefruit juice constituents: decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25: 1228–33PubMedGoogle Scholar
  65. 65.
    Fukuda K, Ohta T, Oshima Y, et al. Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 1997; 7: 391–6PubMedCrossRefGoogle Scholar
  66. 66.
    Edwards DJ, Bellevue FH, Woster PM. Identification of 6,7-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996; 24: 1287–90PubMedGoogle Scholar
  67. 67.
    Sorensen JM. Herb-drug, food-drug, nutrient-drug, and drug-drug interactions: mechanisms involved and their medical implications. J Altern Complement Med 2002; 8 (3): 293–308PubMedCrossRefGoogle Scholar
  68. 68.
    Ernst E. Harmless herbs?: A review of the recent literature. Am J Med 1998; 104: 170–8PubMedCrossRefGoogle Scholar
  69. 69.
    Bottorf MB. Distinct drug-interaction profiles for statins. Am J Health Syst Pharm 1999; 56: 1019–20PubMedGoogle Scholar
  70. 70.
    Iliadis EA, Rosenson RS. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol 1999; 22: 25–8PubMedCrossRefGoogle Scholar
  71. 71.
    McKindley D, Dufresne R. Current knowledge of the cytochrome p-450 isozyme system: can we predict clinically important drug interactions? Med Health R I 1998; 81: 38–42Google Scholar
  72. 72.
    Hansten PD, Horn JR. Drug interactions newsletter (with quarterly updates): a clinical perspective and analysis of current developments. Vancouver: Applied Therapeutics, 1998Google Scholar
  73. 73.
    Lode H. Evidence of different profiles of side effects and drug-drug interactions among the quinolones: the pharmacokinetic standpoint. Chemotherapy 2001; 47 Suppl. 3: 24–31; 44–8CrossRefGoogle Scholar
  74. 74.
    Tatro DS, editor. Drug interaction facts (with quarterly updates). St Louis: Facts and Comparisons, 1998 Oct: 91–92, 609a-10, 685d-g, 714a-bGoogle Scholar
  75. 75.
    Desta Z, Kerbusch T, Soukhova N, et al. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 1998; 285: 428–37PubMedGoogle Scholar
  76. 76.
    Flockhart DA, Richard E, Woosley RL, et al. Metabolic interaction between clarithromycin and pimozide may result in cardiac toxicity [abstract]. Clin Pharmacol Ther 1996; 59: 189AGoogle Scholar
  77. 77.
    Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6. Clin Pharmacol Ther 1999; 65: 10–20PubMedCrossRefGoogle Scholar
  78. 78.
    Daly AK. Molecular basis of polymorphic drug metabolism. J Mol Med 1995; 73: 539–53PubMedCrossRefGoogle Scholar
  79. 79.
    Wormhoudt LW, Commandeur JN, Vermeulen NP. Genetic polymorphism of human N-acetyltransferase, cytochrome P450, glutathione-s-transferase and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol 1999; 29: 59–124PubMedCrossRefGoogle Scholar
  80. 80.
    Ma MK, Woo MH, McLeod HL. Genetic basis of drug metabolism. Am J Jealth syst Pharm 2002; 59 (21): 2061–9Google Scholar
  81. 81.
    Snow J, Gibson L. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol 2995; 32: 114–6CrossRefGoogle Scholar
  82. 82.
    The Medical Letter®. The Medical Letter® handbook of adverse drug interactions, 2003 edition. The Medical Letter, Inc., New Rochelle (NY), 2003Google Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Lori E. Shapiro
    • 1
    • 2
    • 3
    • 4
  • Sandra R. Knowles
    • 3
  • Neil H. Shear
    • 1
    • 2
    • 3
    • 4
    • 5
  1. 1.Division of Clinical PharmacologySunnybrook and Women’s College Health Science Centre and the University of TorontoTorontoCanada
  2. 2.Division of DermatologySunnybrook and Women’s College Health Science Centre and the University of TorontoTorontoCanada
  3. 3.Drug Safety ClinicSunnybrook and Women’s College Health Science Centre and the University of TorontoTorontoCanada
  4. 4.Department of MedicineSunnybrook and Women’s College Health Science Centre and the University of TorontoTorontoCanada
  5. 5.Department of PharmacologySunnybrook and Women’s College Health Science Centre and the University of TorontoTorontoCanada

Personalised recommendations